Antiviral therapy for hepatitis C in the setting of liver transplantation

Current Treatment Options in Gastroenterology

Volumn 9, Issue 6, 2006, Pages 520-529

  Everson, Gregory T ^a   Kulig, Clark C ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; CLOZAPINE; CONSENSUS INTERFERON; CYTOCHROME P450 1A2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; NEUTRALIZING ANTIBODY; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLATELET DERIVED GROWTH FACTOR; PROTEINASE INHIBITOR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBASPHERE; RIBAVIRIN; VIRUS RNA; WARFARIN; ZIDOVUDINE;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; BLOOD TOXICITY; BODY WEIGHT DISORDER; BONE MARROW TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; COUGHING; CYTOPENIA; DEPRESSION; DERMATITIS; DIARRHEA; DIETARY INTAKE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPNEA; ENZYME INHIBITION; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; GRAFT INFECTION; GRAFT SURVIVAL; HEADACHE; HEMOGLOBIN DETERMINATION; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERBILIRUBINEMIA; IMMUNE DEFICIENCY; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; LACTIC ACIDOSIS; LIFESTYLE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MONOTHERAPY; MOOD DISORDER; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROTEINURIA; PRURITUS; PSYCHOSIS; RECURRENT DISEASE; REOPERATION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUICIDAL BEHAVIOR; SURVIVAL TIME; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT DURATION; TREATMENT PLANNING; VIRUS HEPATITIS; VIRUS LOAD; VIRUS STRAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 33751350584     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-006-0008-5     Document Type: Review

References (42)

1. Charlton M: Recurrence of hepatitis C infection: Where are we now? Liver Transpl 2005, 11 (Suppl 2): S57-S62.
2. Ercolani G, Grazi G, Ravaioli M, et al.: Histological recurrent hepatitis C after liver transplantation: outcome and role of retransplantation. Liver Transpl 2006, 12:1104-1111.
3. Neumann UP, Neuhaus P: Course and treatment of recurrent hepatitis C after liver transplantation. Minerva Gastroenterol Dietol 2004, 50:61-66.
4. Wiesner RH, Sorrell M, Villamil F: Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003, 9:S1-S9.
5. Burak KW, Kremers WK, Batts KP, et al.: Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002, 8:362-369.
6. Kato T, Yoshida H, Sadfar K, et al.: Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. Transplant Proc 2005, 37:1217-1219.
7. Strader DB, Wright T, Thomas DL, et al.: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
8. Forns X, Garcia-Retortillo M, Serrano T, et al.: Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003, 39:389-396.
9. Everson GT, Trotter J, Forman L, et al.: Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005, 42:255-262.
10. Crippin JS, McCashland T, Terrault N, et al.: A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002, 8:350-355.
11. Thomas RM, Brems JJ, Guzman-Hartman G, et al.: Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003, 9:905-915.
12. Everson GT: Treatment of hepatitis C in patients who have decompensated cirrhosis. Clin Liver Dis 2005, 9:473-486.
13. Forns X, Navasa M, Rodes J: Treatment of HCV infection in patients with advanced cirrhosis. Hepatology 2004, 40:498.
14. National Institutes of Health. Low accelerating dosage regimen (LADR) ancillary study of the adult to adult living donor liver transplantation study (A2ALL). Available at: www.nih-a2all.org. Accessed June 15, 2006.
15. Hepatitis C long-term treatment against cirrhosis study (HALT-C). Available at: www.haltctrial.org. Accessed June 15, 2006.
16. Study of long-term peg intron vs. colchicine in non-responders (COPILOT). Available at: www.clinical-trials.gov/ct/show/NCT00179413. Accessed June 23, 2006.
17. Afdhal NH, Freilich B, Levine R. Colchicine versus pegintron long-term (COPILOT) trial: interim analysis of clinical outcomes at year 2 [abstract]. Hepatology 2004, 40:238A.
18. Davis GL, Nelson DR, Terrault N, et al.: A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005, 11:941-949.
19. Chalasani N, Manzarbeitia C, Ferenci P, et al.: Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005, 41:289-298.
20. Shergill AK, Khalili M, Straley S, et al.: Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005, 5:118-124.
21. Sugawara Y, Makuuchi M, Matsui Y, et al.: Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004, 78:1308-1311.
22. A study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (ribavirin) administered after liver transplantation for hepatitis C (PHOENIX). Available at: www.clinicaltrials.gov/ct/gui/show/NCT00087633. Accessed June 15, 2006.
23. Samuel D, Bizollon T, Feray C, et al.: Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003, 124:642-650.
24. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al.: Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002, 8:1000-1006.
25. Bizollon T, Ahmed SN, Radenne S, et al.: Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003, 52:283-287.
26. Berenguer M, Prieto M, Palau A, et al.: Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol 2004, 16:1207-1212.
27. Giostra E, Kullak-Ublick GA, Keller W, et al.: Ribavirin/ interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 2004, 17:169-176.
28. Mukherjee S, Lyden E, McCashland TM, Schafer DF: Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients. J Gastroenterol Hepatol 2005, 20:198-203.
29. Burra P, Targhetta S, Pevere S, et al.: Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience. Transplant Proc 2006, 38:1127-1130.
30. Narayanan Menon KV, Poterucha JJ, El-Amin OM, et al.: Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002, 8:623-629.
31. Dumortier J, Scoazec JY, Chevallier P, Boillot O: Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004, 40:669-674.
32. Neff GW, Montalbano M, O'Brien CB, et al.: Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004, 78:1303-1307.
33. Rodriguez-Luna H, Khatib A, Sharma P, et al.: Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004, 77:190-194.
34. Castells L, Vargas V, Allende H, et al.: Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005, 43:53-59.
35. Heydtmann M, Freshwater D, Dudley T, et al.: Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation. Am J Transplant 2006, 6:825-833.
36. Bizollon T, Adham M, Pradat P, et al.: Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C. Transplantation 2005, 79:325-329.
37. Smallwood GA, Davis L, Connor K, et al.: Nonresponders of interferon/ ribavirin treatment for recurrent hepatitis C following liver transplantation. Transplant Proc 2003, 35:1476-1477.
38. Berenguer M, Prieto M, Palau A, et al.: Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006, 12:1067-1076.
39. Carmiel-Haggai M, Fiel MI, Gaddipati HC, et al.: Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl 2005, 11:1567-1573.
40. Walsh MJ, Jonsson JR, Richardson MM, et al.: Nonresponse to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006, 55:529-535.
41. Individualized dosing efficacy vs. flat dosing to assess optimal pegylated interferon therapy (Ideal Study). Available at: www.idealstudy.com. Accessed June 15, 2006.
42. Curry MP, Afdhal NH: Use of growth factors with antiviral therapy for chronic hepatitis C. Clin Liver Dis 2005, 9:439-451.